Justin Chakma Silverback Therapeutics, Inc. (SBTX) insider trading activity

SBTX Quotes by TradingView

Justin Chakma is Chief Business Officer of Silverback Therapeutics, Inc.. Currently has a direct ownership of 136,380 shares of SBTX, which is worth approximately $0. The most recent transaction as insider was on Dec 13, 2024, when has been sold 27,272 shares (Common Stock) at a price of $12.06 per share, resulting in proceeds of $328,900. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 136K
42.3% 3M change
42.3% 12M change
Total Value Held $0

Justin Chakma Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 13 2024
SELL
Open market or private sale
$328,900 $12.06 p/Share
27,272 Reduced 16.66%
136,380 Common Stock
Dec 13 2024
BUY
Exercise of conversion of derivative security
$39,271 $1.44 p/Share
27,272 Added 14.28%
163,652 Common Stock
Dec 12 2024
SELL
Open market or private sale
$1,439,675 $12.27 p/Share
117,333 Reduced 46.25%
136,380 Common Stock
Dec 12 2024
BUY
Exercise of conversion of derivative security
$98,559 $0.84 p/Share
117,333 Added 31.62%
253,713 Common Stock
Dec 10 2024
SELL
Open market or private sale
$657,500 $13.15 p/Share
50,000 Reduced 26.83%
136,380 Common Stock
Dec 10 2024
BUY
Exercise of conversion of derivative security
$42,000 $0.84 p/Share
50,000 Added 21.15%
186,380 Common Stock
Dec 06 2024
SELL
Open market or private sale
$711,500 $14.23 p/Share
50,000 Reduced 26.83%
136,380 Common Stock
Dec 06 2024
BUY
Exercise of conversion of derivative security
$42,000 $0.84 p/Share
50,000 Added 21.15%
186,380 Common Stock
Dec 05 2024
SELL
Open market or private sale
$701,413 $14.13 p/Share
49,640 Reduced 26.69%
136,380 Common Stock
Dec 05 2024
BUY
Exercise of conversion of derivative security
$41,697 $0.84 p/Share
49,640 Added 21.06%
186,020 Common Stock
Dec 04 2024
SELL
Open market or private sale
$627,750 $13.95 p/Share
45,000 Reduced 24.81%
136,380 Common Stock
Dec 04 2024
BUY
Exercise of conversion of derivative security
$37,800 $0.84 p/Share
45,000 Added 19.88%
181,380 Common Stock
Dec 03 2024
SELL
Open market or private sale
$593,550 $13.19 p/Share
45,000 Reduced 24.81%
136,380 Common Stock
Dec 03 2024
BUY
Exercise of conversion of derivative security
$37,800 $0.84 p/Share
45,000 Added 19.88%
181,380 Common Stock
Dec 02 2024
SELL
Open market or private sale
$615,150 $13.67 p/Share
45,000 Reduced 24.81%
136,380 Common Stock
Dec 02 2024
BUY
Exercise of conversion of derivative security
$37,800 $0.84 p/Share
45,000 Added 19.88%
181,380 Common Stock
Nov 27 2024
SELL
Open market or private sale
$359,750 $14.39 p/Share
25,000 Reduced 15.49%
136,380 Common Stock
Nov 26 2024
SELL
Open market or private sale
$592,713 $14.05 p/Share
42,186 Reduced 20.72%
161,380 Common Stock
Nov 25 2024
SELL
Open market or private sale
$459,396 $14.0 p/Share
32,814 Reduced 13.88%
203,566 Common Stock
Nov 08 2022
BUY
Grant, award, or other acquisition
-
236,380 Added 50.0%
236,380 Common Stock
JC

Justin Chakma

Chief Business Officer
San Diego, CA

Track Institutional and Insider Activities on SBTX

Follow Silverback Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SBTX shares.

Notify only if

Insider Trading

Get notified when an Silverback Therapeutics, Inc. insider buys or sells SBTX shares.

Notify only if

News

Receive news related to Silverback Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SBTX